[July 19, 2016]

UPCOMING DEADLINE ALERT - CHIASMA, INC. - Brower Piven Reminds Shareholders of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess of $100,000 To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Chiasma, Inc. (NASDAQ: CHMA) ("Chiasma" or the "Company") securities during the period between July 15, 2015 and April 17, 2016, inclusive (the "Class Period"). Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until August 8, 2016 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Chiasma securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 and the Securities Act of 1933 by virtue of the defendants' failure to disclose in the Registration Statement and Prospectus issued in connection with the Company's initial public offeing on or about July 15, 2015 and during the Class Period, that Chiasma's Phase 3 clinical trial methodology for Mycapssa, an oral octreotide, was not sufficient to demonstrate efficacy and secure U.S. Food and Drug Administration ("FDA") approval and Chiasma's supervision of its suppliers was not sufficient to prevent deficiencies that would delay FDA approval of Mycapssa.

According to the complaint, following an April 18, 2015 announcement that the FDA had issued a Complete Response Letter regarding the New Drug Application for Mycapssa advising that the Company's application did not provide substantial evidence of efficacy to warrant approval, that another clinical trial would need to be conducted, and that certain deficiencies with one of Chiasma's suppliers would need to be resolved before FDA approval, the value of Chiasma's shares declined significantly.

If you have suffered a loss from investment in Chiasma securities purchased on or after July 15, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company's conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160719006456/en/

[ Back To TMCnet.com's Homepage ]